TRACON Pharmaceuticals (TCON) Getting Somewhat Positive Press Coverage, Analysis Shows

News coverage about TRACON Pharmaceuticals (NASDAQ:TCON) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.7121004272952 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

TRACON Pharmaceuticals (NASDAQ:TCON) opened at $2.75 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.80 and a quick ratio of 3.80. TRACON Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $7.07.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.32. The business had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.60 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. equities research analysts forecast that TRACON Pharmaceuticals will post -1.21 earnings per share for the current year.

Separately, Zacks Investment Research raised shares of TRACON Pharmaceuticals from a “sell” rating to a “hold” rating and set a $2.50 price objective on the stock in a report on Saturday, August 12th.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://sportsperspectives.com/2017/11/20/tracon-pharmaceuticals-tcon-getting-somewhat-positive-press-coverage-analysis-shows.html.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply